Abstract
The Israeli Teratogen Information Service prospectively followed up 210 pregnancies with first trimester carbamazepine exposure. Pregnancy outcome was compared with that of two overlapping controls, matched and general (n = 629), exposed to nonteratogenic agents. Our study suggests a twofold increase in the rate of major congenital anomalies (12/160 [carbamazepine] versus 18/560 [general control]; relative risk 2.24; 95% CI 1.1-4.56) and a birth weight reduction of approximately 250 g after in utero exposure to carbamazepine.
Original language | English |
---|---|
Pages (from-to) | 321-324 |
Number of pages | 4 |
Journal | Neurology |
Volume | 57 |
Issue number | 2 |
DOIs | |
State | Published - 24 Jul 2001 |